JAXtaposition - Cancer

In this virtual 'fire-side' discussion, researchers will share how their cutting-edge genomic testing is giving physicians access to the most advanced precision cancer care for their patients.


Mark Adams, Ph.D., Deputy Director, Professor and Director of Microbial Genomic Services at JAX GM

Mark AdamsDr. Mark Adams is Deputy Director, Professor and Director of Microbial Genomic Services at The Jackson Laboratory for Genomic Medicine in Farmington, CT. His group develops and applies approaches to microbial profiling in human studies and develops mouse models for demonstrating the roles of microbes in health and disease states.

Dr. Adams was a co-founder of The Institute for Genomic Research and Celera Genomics, where he led the DNA sequencing and genome annotation groups. From 2003-2011, Dr. Adams was Associate Professor of Genetics at Case Western Reserve University. From 2011-2016, he was the Scientific Director and Professor at the J. Craig Venter Institute. There he directed programs that characterized genomic changes in the evolution of antibiotic resistance in hospital-acquired infections.

Dr. Adams has a BA in Chemistry from Warren Wilson College and a PhD in Biological Chemistry from the University of Michigan.

Francesca Menghi, Ph.D., Associate Research Scientist

Francesca MenghiFrancesca Menghi obtained her B.Sc. and M.Res. from the University of Milan, Italy, where she identified genetic alterations that affect brain cancer patients’ prognosis. She earned her Ph.D. in cancer biology at University College London, where she studied transcriptional changes in childhood brain cancer. In 2010, she joined Dr. Ed Liu’s lab at the Genome Institute of Singapore as a postdoctoral fellow, studying the genome-wide patterns of alterations that are implicated in the origin and evolution of human cancer. In 2013, she joined The Jackson Laboratory for Genomic Medicine in Farmington, Conn., as an associate research scientist.

Click here to view a write-up of the virtual event NEW STRATEGIES FOR TACKLING BREAST CANCER on Thursday, September 24, 2020.

Using genomic research, JAX scientist, Francesca Menghi, Ph.D., wants to identify better treatments for patients diagnosed with triple-negative breast cancer. Join Menghi and Mark Adams, Ph.D., Professor and Director of Microbial Genomic services, and Deputy Director at The Jackson Laboratory for Genomic Medicine, for a virtual conversation about how future research can empower oncologists with a much larger array of therapies for their patients.  

Thursday, September 24, 2020
12:00 PM - 1:00 PM (Eastern Time)

For questions about upcoming events, please contact Erin Bysiewicz by email (erin.bysiewicz@jax.org) or by phone at (860) 837.2487.

  • JAX and the Maine Cancer Genomic Initiative

    Hear from JAX Executive Vice President and Chief Operating Officer, Charles E. Hewett, about the latest cutting edge technologies and newest program that is shaping cancer care in the State of Maine.

  • An end to one-size-fits-all cancer therapies

    In this TED-style talk, learn how JAX is tackling one of the deadliest forms of breast cancer, triple negative breast cancer, from one of our brightest scientists, Francesca Menghi, Ph.D.

  • Mapping a Cancer Free Life

    The future of medicine, is one where we will be able to predict when cancer might occur, treat cancer in real time without guesswork, and prevent cancer from erver happening in the first place. Together, this could create a precise road map for a cancer-free life.  This is the future of your health.

    Jens Rueter, M.D., JAX Medical Director of the Maine Cancer Genomics Initiative (MCGI), and Madeleine Braun, Ph.D., MBA, JAX’s Chief of Presidential Initiatives, gave insight into how we’re mapping a cancer-free life for you and your family, with information about how living well today can impact your health in the future.